Study details
Enrolling now
Methylnaltrexone in Resectable Head and Neck Squamous Cell Carcinoma (MINK). A Window of Opportunity Pilot Study
M.D. Anderson Cancer Center
NCT IDNCT06162377ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
25
Study length
about 3 years
Ages
18+
Locations
1 site in TX
What this study is about
This trial is testing if head and neck squamous cell carcinoma patients can safely receive methylnaltrexone for two weeks before surgery. The goal is to see how well the medication is tolerated, if it works in treating the cancer, and if it affects the tumor's biology.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Methylnaltrexone
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
Gastrointestinal Agent (Opioid Antagonists)
Endpoints
Primary: Safety and adverse events (AEs)
Body systems
Oncology